Orthocell Completes First Remplir Surgery in US Military Hospital System
Orthocell completes first Remplir surgery in US military hospital network
Orthocell Limited has completed the first surgical case using its Remplir nerve repair device within the US Department of Defense (DoD) and Veterans Affairs (VA) hospital network. The surgery was conducted at a military base hospital in Ohio, marking rapid conversion from approval to clinical use within days of the 15 April 2026 procurement clearance. The milestone provides Orthocell access to approximately 221 hospitals across the DoD and VA systems.
The speed of execution demonstrates early surgeon engagement and validates Orthocell’s commercial infrastructure. The company’s US distributor network, which spans 17 states, will now support further uptake of Remplir across military and veteran healthcare facilities whilst maintaining parallel expansion through the broader US hospital system.
Key Commercial Milestones:
| Metric | Detail |
|---|---|
| Hospitals accessible | 221 (51 DoD + 170 VA) |
| US distributor coverage | 17 states |
| Approval date | 15 April 2026 |
| First surgical case | Completed (Ohio) |
When big ASX news breaks, our subscribers know first
What is Remplir and why does peripheral nerve repair matter?
Remplir is a collagen-based medical device designed for peripheral nerve reconstruction. Peripheral nerve injuries can result from trauma, surgical complications, or accidents, leading to loss of sensation or motor function in affected areas. These injuries represent a genuine clinical challenge with limited treatment options available to surgeons.
Military and veteran populations experience disproportionately higher rates of complex trauma cases, making the DoD and VA hospital networks clinically relevant markets for nerve repair technologies. The device addresses a specific medical need in settings where conventional treatments may prove insufficient.
Remplir has secured regulatory clearance for use in the United States through FDA approval. The device is also approved in Australia, New Zealand, Singapore, Canada, Thailand, and Hong Kong, demonstrating regulatory acceptance across multiple jurisdictions.
The next major ASX story will hit our subscribers first
Commercial execution and distribution capability
The first surgical case within the DoD/VA network validates Orthocell’s commercial strategy and surgeon engagement approach. The company’s existing US distributor footprint provides in-theatre case support and facilitates rapid adoption once hospital access is secured.
These same distribution partners will now support further uptake across the DoD and VA systems, creating an additional revenue channel alongside the broader US hospital rollout already underway. The milestone demonstrates Orthocell’s ability to convert regulatory and procurement approvals into revenue-generating surgical activity within compressed timeframes.
Paul Anderson, Managing Director
“We are extremely pleased to see Remplir progress to its first surgical case within the U.S. DoD and VA hospital network so soon after approval, validating our commercial strategy, surgeon engagement, and distribution capability. This milestone highlights both the clinical relevance of Remplir for complex nerve injuries and our ability to execute rapidly once access is secured. Military and veteran healthcare systems manage some of the most challenging trauma cases, and early surgical uptake is an encouraging signal as we continue to expand activity across these hospitals.”
Commercial Progress Components:
- DoD/VA procurement approval secured
- First surgical case completed within days
- Distributor network activated to support further uptake
- Parallel rollout continuing across broader US hospital system
Scaling US revenues across multiple channels
The DoD/VA channel operates as a complementary revenue stream to Orthocell’s existing commercial hospital rollout, rather than replacing it. The company continues to expand hospital access, surgeon engagement, and case activity across the broader US market through its established distributor partnerships.
Orthocell has effectively expanded its addressable market without requiring additional regulatory clearances. The 221 hospitals now accessible through the DoD and VA systems represent incremental opportunity beyond the company’s current commercial footprint spanning 17 US states.
The company will work closely with distribution partners to support further uptake across both military/veteran healthcare facilities and the broader commercial hospital network. This dual-channel approach allows Orthocell to target multiple patient populations and clinical settings simultaneously, building scale in the US nerve repair market.
Want to Track Orthocell’s US Commercial Rollout as Surgical Cases Scale?
Orthocell has converted DoD and VA procurement approval into surgical activity within days, demonstrating execution capability across 221 military and veteran hospitals. The company’s established distributor network now supports parallel revenue channels in both defence healthcare systems and the broader US commercial market.
To monitor further surgical uptake, revenue progression, and expansion across Orthocell’s dual-channel US strategy, visit the Orthocell investor centre for company announcements, distribution updates, and clinical milestones.